Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00257972 · ClinicalTrials.gov registry record · Phase 3
Study of Aripiprazole in Patients With Bipolar I Disorder
A Phase 3 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
NCT00257972 is a Phase 3 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 400 participants.
The verdict
NCT00257972, a Phase 3 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
Study Summary
The purpose of this research study is to compare the efficacy of aripiprazole with placebo in combination with lithium or valproate monotherapy, in the treatment of bipolar I patients with manic or mixed episodes.
Interventions
- DRUG aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2004-10 |
| Est. Completion | 2007-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00257972
The ClinicalTrials.gov registry entry for NCT00257972 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which aripiprazole is the first listed.
NCT00257972 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00257972 about?
NCT00257972 is a clinical study titled "Study of Aripiprazole in Patients With Bipolar I Disorder". The purpose of this research study is to compare the efficacy of aripiprazole with placebo in combination with lithium or valproate monotherapy, in the treatment of bipolar I patients with manic or mixed episodes.
What is the current status of trial NCT00257972?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2004-10. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00257972?
The interventions under investigation include: aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00257972?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.